South African coronavirus variant found in the Netherlands The South African variant of the coronavirus (501Y.V2) has been identified in the Netherlands for the first time.
Update on the spread of the UK coronavirus variant (VOC 202012/01) in the Netherlands The number of people that have been found to have the new SARS-CoV-2 coronavirus variant designated VOC 202012/01 (the UK variant) has risen from 11 to nearly 50 individuals.
First COVID-19 vaccination in the Netherlands given at GGD vaccination site in Veghel Care workers in nursing homes and small-scale residential facilities received the first COVID-19 vaccinations in the Netherlands this morning at the GGD vaccination location ‘Hart voor Brabant’ in
Decisive decrease not yet visible Decisive effects from the lockdown of 15 December have yet to be seen. Although there was a decrease in the number of people who were tested and the number of people who tested positive for COVID-19.
Care workers in nursing homes and small-scale residential facilities invited for COVID-19 vaccination starting today As of today, the ca. 269,000 care workers of nursing homes and small-scale residential facilities in the Netherlands are invited to make an appointment for a COVID-19 vaccination.
RIVM to research safe design for new nanoparticles RIVM will be working alongside a consortium of 23 international partners on a safe design for ‘new’ nanoparticles.
Breast milk as indicator of environmental pollutants The 6th worldwide study into Persistent Organic Pollutants (POPs) in breast milk is about to commence.
The National Immunisation Programme in the Netherlands: Developments in 2013 Annually RIVM provides an overview of key events and developments in the National Immunisation Programme (NIP).
Preserving ozone treaty benefits to climate change The Montreal Protocol has not only served to protect the ozone layer, it also has provided a certain degree of climate protection.
Combating the Superbug Klebsiella Oxa-48 Outbreak in a Dutch Hospital Experts at RIVM teamed up with scientists of the Medical Faculty of the University Münster (Germany), and bioinformaticans from Life Technologies Corporation (United States of America) and the Well